Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Roche Valcyte Expected To Erode Ganciclovir Scripts After Spring Launch

  • News

Executive Summary

Roche anticipates that Valcyte (valganciclovir) will begin to erode oral Cytovene (ganciclovir) prescriptions for the treatment of cytomegalovirus retinitis in AIDS patients following spring launch.

You may also be interested in...



Cytovene I.V. Shortage Will Be Resolved by Second Quarter, Roche Says

Roche expects to resolve a shortage of Cytovene I.V. by the second quarter

Cytovene I.V. Shortage Will Be Resolved by Second Quarter, Roche Says

Roche expects to resolve a shortage of Cytovene I.V. by the second quarter

Roche Valganciclovir Phase IV Studies Should Investigate HAART Effect

Roche valganciclovir Phase IV studies should address the effect of highly active antiretroviral therapy on the drug's efficacy for maintenance therapy in cytomegalovirus retinitis, FDA's Antiviral Drugs Advisory Committee said at its Feb. 27 review of the drug's NDA.

Table

View full table

Tags:
Latest Headlines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Global Pharma Guidance Tracker – March 2024

See All
UsernamePublicRestriction

Register

PS037603

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By